A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells

This publication has 26 references indexed in Scilit:

• The toxicity and mutagenicity of the anti-tumour drug 5-aziridino-2, 4-dinitrobenzamide (CB1954) is greatly reduced in a nitroreductase-deficient strain of E. coli
  Mutagenesis, 1987
• CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells
  Biochemical and Biophysical Research Communications, 1986
• CB 1954 revisited
  Cancer Chemotherapy and Pharmacology, 1986
• CB 1954 revisited
  Cancer Chemotherapy and Pharmacology, 1986
• Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954)
  Biochemical Pharmacology, 1980
• Studies on the reversal of the selective antitumour effect of the aziridinyl derivative cb 1954 by 4‐amino‐5‐imidazolecarboxamide
  International Journal of Cancer, 1972
• The differential response of resistant and sensitive strains of Escherichia coli to the cytotoxic effects of 5-aziridino-2,4-dinitrobenzamide (CB 1954)
  Chemico-Biological Interactions, 1971
• Quantitative aspects of the repair of alkylated DNA in cultured mammalian cells
  Chemico-Biological Interactions, 1971
• Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the walker tumour
  International Journal of Cancer, 1971
• 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256
  Biochemical Pharmacology, 1969